The United Kingdom and the United States have signed a major bilateral deal that will keep zero tariffs on UK pharmaceutical products being sold in the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to boost expenditure on drugs through the public health system. This move ensures that import taxes on these vital goods will stay at zero for a timeframe of the next three years.
This agreement is in response to earlier threats to dramatically increase duties on patented pharmaceutical products, with potential rates discussed as high as 100%.
"This agreement between the UK bolsters the global environment for new treatments and brings much-needed balance to American-British drug exports," a release declared.
Commercial Impact
Medicines are one of the Britain's biggest exports to the America, which is easily the primary market for major British pharmaceutical firms.
Export figures show that in the 12 months prior to last September, the UK exported medicines totaling £11.1bn to the US. This amount accounted for nearly one-fifth of British export trade in that timeframe.
"This deal safeguards work, increases funding and facilitates the UK to become a international leader for medical research," a minister stated.
Key UK Commitments
The pact involves several key pledges from the UK:
- Price Threshold Increase: The UK will lift the price threshold at which it considers new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a aim to increase total NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The amount drug companies must refund to the NHS to prevent overspending will be restricted at fifteen percent. Previously, rebates were more than 20%.
Recent Tensions
The pact follows a long-running dispute between the sector and the ministers over spending levels and NHS adoption.
These tensions were intensified by claims that US patients were charged a premium for the equivalent treatments than consumers in the UK and Europe.
Recently, several large drug company projects in the UK have been paused or scrapped, while major investments have been directed toward American operations.
The Science Minister acknowledged that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had decreased as a proportion of its overall budget over the past decade.
